On behalf of the European Commission, HaDEA has published new open calls for proposals covering nine topics outlined in the 2025 EU4Health Work Programme and based on DG SANTE policy priorities.

Pfizer is launching a competitive grant program to support Investigator’s Sponsored Research (ISR) projects aimed at collecting real-world data (RWD) emerging from the on-label abrocitinib (200 mg and 100 mg) indication to adult patients (≥18 years) with Atopic Dermatitis (AD) in the Italian clinical practice. The intent of this RFP is to encourage proposals that align with current therapeutic guidelines and address unmet needs in the Italian clinical scenario. Applicants are encouraged to submit projects aimed at generating real-world evidence (RWE) to address current gaps in the management of AD in Italy, with a specific focus on abrocitinib, to further investigate its effectiveness and safety.

Strategic projects for capitalisation are to take up existing Interreg transnational and cross-border outputs and results, to meet existing and new needs and strengthen their territorial and policy impact in wider areas, also beyond border regions. They must go beyond a mere pooling or duplication of what already exists. Instead, they should further develop, improve, or adapt existing outputs and results by drawing on the experience of more projects. As a minimum requirement, projects must explicitly take up existing outputs and results from: At least two Interreg CENTRAL EUROPE projects funded under the first and second calls of the 2021–2027 programme, and at least two Interreg cross-border cooperation projects (funded in the 2021-2027 period or, if relevant, in the 2014-2020 period), addressing internal central European borders.